Preview cover for "Antibody-drug Conjugates: ‘Magic Bullets’ Become Reality" white paper

ADCs consist of three components: an antibody, a linker, and a payload. An antibody against a tumor antigen acts as a targeted delivery system, guiding the ADC directly towards antigen-expressing tumor cells, avoiding toxicity to healthy cells and unwanted side effects.

About the authors

Headshot image of Jon Stephens

Jon Stephens

Associate Director & Taxonomist, Pharmaprojects

Jonathan Stephens is Associate Director for Pharmaprojects,
managing a team of drug analysts and overseeing scientific
data enhancements and taxonomy projects. In addition to
collaborating with product development, he also serves Citeline
clients in drug-related Ask the Analyst service, providing insight
into optimal search strategies and drug development landscapes
to address their strategic business needs. Jonathan has been
with Pharmaprojects since 2007 and has bachelor’s and master’s
of philosophy degrees in pharmacology from University of
Portsmouth.

Headshot image of Arbesa Bela

Arbesa Bela

Drug Analyst II, Pharmaprojects

Arbesa Bela is a Drug Analyst II for Pharmaprojects, involved in
various data enhancement projects and supporting the Ask the
Analyst Service. She engages in drug landscape analyses and
expert subject matter queries in the cardiometabolic, infectious,
and genitourinary disease space. Arbesa joined Pharmaprojects
in 2023 and has a degree in bioprocessing of new medicines from
University College London.

Related resources

ASCO 2024 Key Highlight
JUL 15, 2024
Infographic
Clinical

ASCO 2024 Key Highlights

This summary examines the clinical trial environment for industry-sponsored trials with data showcased at ASCO 2024.

Cycle for the destruction of cancer cells
JUL 09, 2024
Article
Clinical

Disparities, Not Diversity, Surround CAR-T Cell Therapy

Despite the potential of Chimeric antigen receptor T cell therapy (CAR-T cell therapy), access remains highly restricted, particularly among minority and vulnerable populations.

radiopharmaceuticals_for_cancer_resource-card-thumbnail
FEB 01, 2022
Article
Clinical

Radiopharmaceuticals: A New Approach to Cancer Treatment

Radiopharmaceutical therapy is an emerging targeted approach to treat cancer, whose potential with specific tumor-associated targets is being recognized.